SCHEMBL4130255

SCHEMBL4130255

CCCCC/C=C(\C)[C]=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.47
TSHR P16473 1/20 0.41
FAAH O00519 4/20 0.37
TRPV1 Q8NER1 1/20 0.37
TERT O14746 3/20 0.36
PTPN1 P18031 3/20 0.36
CYP1A2 P05177 2/20 0.36
MAPT P10636 2/20 0.36
CYP2C19 P33261 2/20 0.36
BLM P54132 2/20 0.36
HSD17B10 Q99714 2/20 0.36
FABP4 P15090 2/20 0.36
PPARG P37231 2/20 0.36
KMT2A Q03164 2/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130257 1.00 EP300 (0.47) EP300TSHRFAAHTRPV1TERT
SCHEMBL6053800 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL16431472 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL6053797 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL9262181 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL17240914 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL9262187 0.98 EP300 (0.50) EP300TSHRFAAHTRPV1TERT
SCHEMBL4145192 0.93
SCHEMBL9380581 0.93
SCHEMBL4145193 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192153-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2009-07-30 US disclosed
US-20090118263-A1 Novel Adenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-05-07 US disclosed
US-20090105212-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2009-04-23 US disclosed
US-20090099216-A1 NOVEL ADENINE COMPOUND ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) 2009-04-16 US disclosed
US-20080269240-A1 Novel Adenine Compound Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2008-10-30 US disclosed
EP-1939198-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939199-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939202-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939200-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939201-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269240-A1 Novel Adenine Compound ADORA1, ADORA2A, ADORA3 EP300 1419/4885TSHR 2895/4885FAAH 2347/4885
US-20090118263-A1 Novel Adenine Compound ADORA1, ADORA2A, ADORA3 EP300 2214/4885TSHR 3415/4885FAAH 2884/4885
US-20090099216-A1 NOVEL ADENINE COMPOUND ADORA1, CXCR6, NR0B1 EP300 706/4885TSHR 1269/4885FAAH 3442/4885
US-20090105212-A1 NOVEL ADENINE COMPOUND XDH, ADORA1, NUDT1 EP300 967/4885TSHR 3563/4885FAAH 3047/4885
US-20090192153-A1 NOVEL ADENINE COMPOUND ADORA1, SLC28A1, ADORA2A EP300 2341/4885TSHR 3960/4885FAAH 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.